MedCity News June 9, 2024
Frank Vinluan

Geron Corporation’s Rytelo is now FDA approved for treating anemia caused by myelodysplastic syndromes. The new drug will compete against Reblozyl, a blockbuster Bristol Myers Squibb medicine.

The FDA has approved a Geron Corporation treatment for anemia stemming from a particular type of blood cancer, giving the company its first commercialized product and the opportunity to compete against a blockbuster Bristol Myers Squibb drug.

The Geron drug, imetelstat, is approved to treat adults with low- to intermediate-risk myelodysplastic syndromes. The regulatory decision comes three months after an FDA advisory committee voted that the benefits of the drug outweigh its risks. Foster City, California-based Geron will commercialize its new drug under the brand name Rytelo.

Myelodysplastic syndromes (MDS) are a group...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle
Will Trump Drug Tariffs Help Or Hurt The U.S.?
Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy
Walgreens To Be Acquired By PE Firm Sycamore Partners Amid Shift In Health Care Strategy
First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A Deal

Share This Article